Loading
NNC0487-0111 / Osteoarthritis, Knee / Obesity · Phase 3 Trial
ClinicalTrials.gov · August 17, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a registered Phase 3 randomized controlled trial of NNC0487-0111, a novel investigational drug, in patients with obesity or overweight and knee osteoarthritis. No results are yet available; the study is recruiting and designed to measure relative body weight change and pain (WOMAC NRS) over 80 weeks against placebo. The registry entry documents the study plan only and carries no evidence of efficacy or safety.
Phase 3, Interventional, Randomized, Parallel, Quadruple masking, Treatment purpose. Obesity, Overweight, Osteoarthritis, Knee; age from 18 Years. Intervention: NNC0487-0111. Compared with: Placebo — Placebo Comparator. n = 400. 81 sites across 11 countries.
This is a registered Phase 3 randomized controlled trial of NNC0487-0111, a novel investigational drug, in patients with obesity or overweight and knee osteoarthritis. No results are yet available; the study is recruiting and designed to measure relative body weight change and pain (WOMAC NRS) over 80 weeks against placebo. The registry entry documents the study plan only and carries no evidence of efficacy or safety.
This is a registry record only; no efficacy, safety, or outcome data are reported. Effect sizes, p-values, confidence intervals, and safety events cannot be assessed until results are posted.
The source did not state who this applies to in practice.
This is a clinical trial registry record describing a planned Phase 3 study with no results reported; the study is actively recruiting and outcome data are not yet available.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07509307). This is a study registration, not published results. Lead sponsor: Novo Nordisk A/S. Recruitment status: RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 400 participants (ESTIMATED). Conditions: Obesity, Overweight, Osteoarthritis, Knee. Interventions: DRUG: NNC0487-0111; DRUG: Placebo (matched to NNC0487-0111). Primary outcome measures: Relative change in body weight , From baseline (week 0) to week 80; Change in Western Ontario and McMaster Universities Osteoarthritis Index Numerical Rating Scale (NRS) 3.1 (24-hour) (WOMAC) pain score , From baseline (week 0) to week 80. Brief summary: This study is being done to look at the safety and effect of NNC0487-0111 in people with excess body weight and knee osteoarthritis when compared to placebo. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111, (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.